We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
HUTCHMED China Limited | NASDAQ:HCM | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
0.01 | 0.05% | 18.73 | 18.06 | 18.88 |
High Price | Low Price | Open Price | Traded | Last Trade |
---|---|---|---|---|
18.86 | 18.11 | 18.11 | 92,595 | 01:00:00 |
Date | Time | Source | Headline |
---|---|---|---|
11/1/2024 | 07:00 | RNSNON | Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China |
13/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Completed Enrollment of Phase II/III Trial |
01/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at Congresses |
16/10/2023 | 09:30 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at ESMO 2023 |
29/9/2023 | 09:30 | RNSNON | Hutchmed (China) Limited NDA Submission for Fruquintinib in Japan |
12/9/2023 | 09:30 | RNSNON | Hutchmed (China) Limited Phase IIIb Savolitinib Results at WCLC 2023 |
12/9/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Patient Enrollment Completed for Bridging Study |
29/8/2023 | 07:00 | RNSNON | Hutchmed (China) Limited BTD in China for Savolitinib for Gastric Cancer |
20/7/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Breakthrough Therapy Designation for Fruquintinib |
10/7/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Phase 1 Study of HMPL-415 Initiated |
1 Year HUTCHMED China Chart |
Intraday HUTCHMED China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions